Kumthorn Malathum

Kumthorn Malathum

Auto-generated profile, based on publicly available information

Kumthorn Malathum

Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2019 in Antimicrobial Resistance & Infection Control
Verified
Journal Article
Open access
PDF file
NYNorihisa Yamamoto
Norihisa Yamamoto
SHShigeto Hamaguchi
Shigeto Hamaguchi
YAYukihiro Akeda
Yukihiro Akeda
PSPitak Santanirand
Pitak Santanirand
NCNarong Chaihongsa
Narong Chaihongsa
KTKazunori Tomono
Kazunori Tomono
Active surveillance has the potential to prevent nosocomial transmission of carbapenem-resistant Acinetobacter baumannii (CRAB). We assessed whether rapid diagnosis using clinical specimen-direct loop-mediated isothermal amplification (LAMP), a rapid molecular diagnostic assay, and subsequent intervention, could reduce CRAB nosocomial transmission in intensive care units (ICUs). A before and after (quasi-experimental) study was conducted in two ICUs at the Mahidol University Faculty of Medicine Ramathibodi Hospital with 3 months of observational period followed by 9 months of interventional period. All patients were screened for CRAB using both the culture and LAMP method from rectal swab and/or bronchial aspirates (intubated patients only) upon admission, weekly thereafter, and upon discharge. During the pre-intervention period, we performed contact precautions based on culture results. In contrast, during the intervention period, we initiated contact precautions within a few hours after sample collection on the basis of LAMP results. A total of 1335 patients were admitted to the ICUs, of which 866 patients (pre-intervention period: 187; intervention period: 679) were eligible for this study. Incidence rate of CRAB infection decreased to 20.9 per 1000 patient-days in the intervention period from 35.2 in the pre-intervention period (P < 0.02). The calculated hazard ratio of CRAB transmission was 0.65 (95% confidence interval [CI], 0.44–0.97). Risk factors for CRAB acquisition included exposure to carbapenem (hazard ratio, 2.54 [95% CI: 1.61–5.57]). LAMP screening for CRAB upon ICU admission proved feasible for routine clinical practice. Rapid screening using LAMP followed by early intervention may reduce CRAB transmission rates in ICUs when compared to conventional intervention.

8 March 2019 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
TPTuangrat Phodha
Tuangrat Phodha
ARA. Riewpaiboon
A. Riewpaiboon
KMK. Malathum
K. Malathum
PCP. C. Coyte
P. C. Coyte
Antimicrobial resistance is a major health threat worldwide as it brings about poorer treatment outcome and places economic burden to the society. This study aims to estimate the annual relative increased in inpatient mortality from antimicrobial resistant (AMR) nosocomial infections (NI) in Thailand. A retrospective cohort study was conducted at Ramathibodi Hospital, Bangkok, Thailand, over 2008–2012. Survival model was used to estimate the hazard ratio of mortality of AMR relative to those patients without resistance (non-AMR) after controlling for nine potential confounders. The majority of NI (73.80%) were caused by AMR bacteria over the study period. Patients in the AMR and non-AMR groups had similar baseline clinical characteristics. Relative to patients in the non-AMR group, the expected hazard ratios of mortality for patients in the AMR group with Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus were 1.92 (95% CI 0.10–35.52), 1.25 (95% CI 0.08–20.29), 1.60 (95% CI 0.13–19.10) and 1.84 (95% CI 0.04–95.58), respectively. In the complete absence of AMR bacteria, this study estimated that annually, in Thailand, there would be 111 295 fewer AMR cases and 48 258 fewer deaths.

1 January 2007 in AIDS Research and Therapy
Verified
Journal Article
Open access
PDF file
SSSomnuek Sungkanuparph
Somnuek Sungkanuparph
SKSasisopin Kiertiburanakul
Sasisopin Kiertiburanakul
AAAnucha Apisarnthanarak
Anucha Apisarnthanarak
KMKumthorn Malathum
Kumthorn Malathum
SWSiriorn Watcharananan
Siriorn Watcharananan
BSBoonmee Sathapatayavongs
Boonmee Sathapatayavongs
Non-nucleoside reverse transcriptase inhibitor (NNRTI) with stavudine and lamivudine is widely used as the first-line antiretroviral therapy (ART) in resource-limited settings. Lipodystrophy is common and options for switching ART regimen are limited; this situation can lead to patients' poor adherence and antiretroviral resistance. Treatment interruption (TI) in patients with high CD4 cell counts, lipodystrophy, and limited options may be an alternative in resource-limited settings. This study aimed to determine time to resume ART after TI and predictors for early resumption of ART in a resource-limited setting.

1 February 2016 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
APAngsana Phuphuakrat
Angsana Phuphuakrat
PNPintip Ngamjanyaporn
Pintip Ngamjanyaporn
KNKanokrat Nantiruj
Kanokrat Nantiruj
VLVoravich Luangwedchakarn
Voravich Luangwedchakarn
KMKumthorn Malathum
Kumthorn Malathum
Septic arthritis caused by Streptococcus pneumoniae is uncommon. Most of the patients who have invasive pneumococcal infection have underlying diseases associated with impaired immune function. We report a case of polyarticular pneumococcal septic arthritis in a previously healthy adult as the first manifestation of selective immunoglobulin (Ig)M deficiency. The patient had no evidence of autoimmune disease or malignancy. Serum IgG, IgA, and complement levels were normal. Numbers of lymphocyte subsets were in normal range except that of CD4+ cells, which was slightly low. Invasive pneumococcal disease in a healthy adult should lead to further investigation for underlying diseases including primary immunodeficiencies.

1 July 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
SBSarinya Boongird
Sarinya Boongird
CSChavachol Setthaudom
Chavachol Setthaudom
RKRungthiwa Kitpermkiat
Rungthiwa Kitpermkiat
SPSomsak Prasongtanakij
Somsak Prasongtanakij
SSSupanart Srisala
Supanart Srisala
JBJackrapong Bruminhent
Jackrapong Bruminhent
The durability of a three-dose extended primary series of COVID-19 vaccine in dialysis patients remains unknown. Here, we assessed dynamic changes in SARS-CoV-2-specific humoral and cell-mediated immunity at baseline, 3 months, and 6 months after the extended primary series in 29 hemodialyzed (HD), 28 peritoneal dialyzed (PD) patients, and 14 healthy controls. Participants received two doses of inactivated SARS-CoV-2 vaccine followed by a dose of ChAdOx1 nCoV-19 vaccine. At 6 months, median anti-RBD IgG titers (IQR) significantly declined from baseline in the HD (1741 (1136–3083) BAU/mL vs. 373 (188–607) BAU/mL) and PD (1093 (617–1911) BAU/mL vs. 180 (126–320) BAU/mL) groups, as did the mean percent inhibition of neutralizing antibodies (HD: 96% vs. 81%; PD: 95% vs. 73%) (all p < 0.01). Age and post-vaccination serological response intensity were predictors of early humoral seroprotection loss. In contrast, cell-mediated immunity remained unchanged. In conclusion, humoral immunity declined substantially in dialysis patients, while cell-mediated immunity remained stable 6 months after the extended heterologous primary series of two inactivated SARS-CoV-2/ChAdOx1 nCoV-19 vaccine. A booster dose could be considered in dialysis patients 3 months after this unique regimen, particularly in the elderly or those with a modest initial humoral response.

1 December 2018 in Infection, Disease & Health
Verified
Journal Article
Closed access
NSNantanit Sutthiruk
Nantanit Sutthiruk
JCJulie Considine
Julie Considine
AHAna Hutchinson
Ana Hutchinson
ADAndrea Driscoll
Andrea Driscoll
KMKumthorn Malathum
Kumthorn Malathum
MBMari Botti
Mari Botti